arrow
S

Shengyun Liu

Chinese Academy of Sciences
H指数:19
被引数:1,403

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Firsekibart as a Prophylactic Treatment for Acute Gout Flare in Participants Initiating Urate-Lowering Therapy: A Phase 2, Randomized, Open-Label, Multicenter, Active-Controlled Trial

Firsekibart作为预防性治疗,用于启动降尿酸治疗患者的急性痛风发作:一项2期、随机、开放标签、多中心、活性对照试验

2025-11-070
OAAI
Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients with Active Ankylosing Spondylitis: Results from an Adaptive Seamless Phase II/III Trial

伊娃马西替尼(Ivarmacitinib)的疗效与安全性:一项适应性无缝II/III期试验在活动性强直性脊柱炎患者中的结果

2025-06-120
PRE
A guideline on biomarkers in the diagnosis and evaluation in axial spondyloarthritis
2024-10-301
OAAI
Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial
2024-01-016
PRE
Latent Tuberculosis Infection and Associated Factors in Patients with Systemic Lupus Erythematosus: a Multicenter, Cross-Sectional Study

系统性红斑狼疮患者潜伏性结核感染及相关因素: 一项多中心、横断面研究

2023-06-154
OAAI
Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study
2022-11-081
OAAI
Chinese SLE Treatment and Research Group Registry (CSTAR) XIV: the subjective well-being of patients with systemic lupus erythematosus

中国SLE治疗和研究小组注册 (CSTAR) XIV: 系统性红斑狼疮患者的主观幸福感

2022-09-202
OAAI
Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII

系统性红斑狼疮 (SLE) 的性别差异: 中国SLE治疗和研究小组 (CSTAR) 注册XVII的初始队列

2022-09-206
OAAI
A clinical practice guideline for the screening and assessment of enthesitis in patients with spondyloarthritis
2022-09-125
OAAI
Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China
2021-12-0622
OAAI